Calcium channel 'switches' in head and neck cancer reveal new precision therapy targets

What is it about?

Head and neck cancer — which includes cancers of the mouth, throat, and voice box — is one of the most common cancers worldwide, causing over 450,000 deaths each year. Despite advances in treatment, outcomes for patients with advanced disease remain poor. One reason is that these tumors are not all the same: different tumors carry different genetic mutations, which makes them behave differently and respond differently to treatment. This study investigates a cellular pathway called Store-Operated Calcium Entry (SOCE) — a system of protein "gates" that control how calcium flows into cancer cells. Calcium is a vital signal inside cells that drives growth, movement, and survival. We analyzed gene activity data from over 500 head and neck cancer patients (from The Cancer Genome Atlas, TCGA) and performed laboratory experiments using two cancer cell lines representing different tumor types. We discovered that these calcium gates are reprogrammed in head and neck cancer in a pattern that depends on the tumor's specific genetic background. The main "on-switch" protein (STIM1) is turned down in nearly 40% of tumors, particularly in aggressive and late-stage disease, while other gate proteins (ORAI1–3 and STIM2) are turned up. Tumors with a specific mutation called PIK3CA H1047R appear especially "addicted" to this calcium signaling. When we blocked these calcium gates using a drug called 2-APB, cancer cells stopped growing, moving, and forming new colonies — with PIK3CA-mutant cells showing the greatest sensitivity.

Featured Image

Photo by CDC on Unsplash

Photo by CDC on Unsplash

Why is it important?

Most previous research treated SOCE simply as an "always-on" signal in cancer. Our study is the first to demonstrate that in head and neck cancer, the calcium signaling machinery undergoes a complex, context-dependent reorganization—not a simple increase, but a coordinated switch between different protein types depending on the tumor's oncogenic driver, such as PIK3CA mutation versus EGFR overexpression. This finding carries several important implications. The pattern of STIM1 loss combined with increased expression of ORAI2/3 and STIM2 shows a strong association with aggressive tumor features, including advanced stage, poor differentiation, and basaloid subtype. These changes in the SOCE components therefore offer a promising opportunity to develop new biomarkers that could help identify high-risk patients who are most likely to benefit from targeted therapies. Furthermore, not all head and neck tumors rely on calcium signaling to the same degree. Our results indicate that tumors harboring PIK3CA mutations—present in approximately 10–20% of HNSCC cases—may be particularly dependent on this pathway and thus especially vulnerable to calcium channel blockade. This observation supports a precision medicine approach in which patients could be matched to appropriate treatments according to the molecular profile of their tumor. The work also suggests a rationale for combination therapies. SOCE inhibitors could potentially be paired with existing PI3K/AKT inhibitors or EGFR-targeted agents to help overcome resistance mechanisms and improve outcomes, particularly in aggressive or metastatic head and neck cancer. Finally, head and neck cancers disproportionately burden populations in low- and middle-income countries, including regions across the Middle East, Asia, and Africa. Conducted at Jordan University of Science and Technology, this study delivers a translational research framework that can contribute to global efforts in cancer care.

Perspectives